ArticleNPJ Parkinson's disease2026
Predictors of motor outcome with pallidal stimulation for Parkinson's disease from the CSP468 cohort.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep brain stimulation (DBS) of the globus pallidus interna (GPi) is an effective treatment for medication‑refractory Parkinson's disease (PD), though outcomes vary widely. The influence of lead location relative to the GPi therapeutic sweetspot has not previously been examined within a multivariable regression framework. This study evaluated the predictive utility of volume-of-tissue-activated (VTA)-sweetspot overlap on postoperative UPDRS‑III outcomes in the CSP #468 cohort receiving bilateral GPi‑DBS, alongside demographic/clinical predictors, using two independently derived sweetspot models. CSP #468 was a multicenter randomized clinical trial with blinded 6‑month outcomes and robust collection of associated features of PD. A prior publication generated a cross validated 6‑month GPi-sweetspot from this dataset. An independent single‑surgeon cohort was used to construct a separate sweetspot uninfluenced by CSP outcomes. Multivariable modeling was completed using backward‑selection linear regression with Bonferroni correction. Models were checked for assumptions, data leakage, and overfitting. Each sweetspot-multivariable model's ability to predict outcomes in the opposite cohort was assessed. Both sweetspots localized to the primary motor GPi. The independent sweetspot multivariable model included VTA‑sweetspot overlap and levodopa response (R²
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.